Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | HEXA | P06865 | 1/20 | 0.37 |
| ▸ | HEXB | P07686 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602292 | 0.83 | LOXL2 (0.46) | LOXL2CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL13545272 | 0.80 | LOXL2 (0.41) | LOXL2CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3587653 | 0.77 | POLB (0.38) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL14277003 | 0.76 | POLB (0.61) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL3600670 | 0.75 | TRPV1 (0.40) | — | |
| SCHEMBL282756 | 0.71 | KMT2A (0.39) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL3605571 | 0.71 | CHRM1 (0.40) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL3599798 | 0.71 | ATAD2 (0.46) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL6425342 | 0.69 | CHRM2 (0.42) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL6425343 | 0.68 | CHRM2 (0.38) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | LOXL2 771/4885CHRM1 94/4885CHRM2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.